Latest News for: mtap

Edit

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers (IDEAYA Biosciences Inc)

Public Technologies 15 Jun 2026
IDE892 monotherapy expansion is anticipated in Q3 2026 MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC) ... Loss of MTAP leads to the ...
Edit

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

PR Newswire 15 Jun 2026
IDE892 monotherapy expansion is anticipated in Q3 2026 MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC) ... Loss of MTAP leads to ...
Edit

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

PR Newswire 03 Jun 2026
"We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC," said Yujiro S ... MTAP deletion is estimated to occur in up to 40% of PDAC and almost all MTAP-deleted PDAC harbor co-occurring RAS mutations.
Edit

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion (Foundation Medicine Inc)

Public Technologies 21 Apr 2026
BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy.
Edit

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

PR Newswire 09 Mar 2026
... and observed single-digit nano-molar potency in endogenous MTAP-deleted cell lines, and greater than 50-fold potency differential in MTAP-deleted versus MTAP wild type HCT116 isogenic cell lines.
  • 1

Article Search

tools
×
×
×
×